Kogenate (Octocog alfa)

Brand Options

arrow pointer

Brand Name : Kogenate

Marketing Authorization Holder : Bayer

Prescription Required

Temp Controlled Express Courier

 
 
No Generic Medicine available for this medicine.

Product Details

Kogenate

Information about Kogenate (Octocog Alfa)

Kogenate is a recombinant clotting factor VIII product used to prevent and control bleeding in patients with hemophilia A. It is produced using advanced biotechnology methods to ensure high purity and effectiveness.

Product Highlights

Indicated for the treatment and prevention of bleeding episodes in patients with hemophilia A, including those undergoing surgery.

Key Ingredient

  • Octocog Alfa

Key Benefits

  • Helps control and prevent bleeding episodes in patients with hemophilia A.
  • The recombinant nature may lower the risk of inhibitor development compared to plasma-derived products.
  • Allows for individualized dosing based on patient needs and response.

Direction of Use

  • Dosage varies based on the severity of hemophilia, body weight, and the type of bleeding episode; determined by a healthcare provider.
  • After reconstituting the powder, administer the solution intravenously. Rotate injection sites to minimize discomfort.

Available dosage strengths and approximate concentration of reconstituted KOGENATE.

KOGENATE Dose StrengthsConcentration of Reconstituted KOGENATE
250 International Units (IU)~ 100 IU/mL
500 International Units (IU)~ 200 IU/mL
1000 International Units (IU)~ 400 IU/mL
2000 International Units (IU)~ 400 IU/mL
3000 International Units (IU)~ 600 IU/mL

Safety Concerns

  • Potential for allergic reactions, including anaphylaxis in rare cases; monitor for signs of hypersensitivity.
  • Some patients may develop inhibitors against factor VIII, which can reduce the effectiveness of treatment.
  • Caution in patients with a history of thromboembolic disorders; may require monitoring.

Avoid Kogenate (Octocog Alfa) If

  • Patients with a known allergy to octocog alfa or any component of the formulation should avoid use.
  • Should not be used in patients with a history of or active thromboembolic events unless advised by a healthcare provider.
  • Caution is advised in patients with significant liver impairment due to potential complications in coagulation.
This product requires special packaging to maintain its integrity during the shipping process. DO NOT USE THIS MEDICATION if the attached temperature indicator shows that the medication was exposed to temperatures below 2 degrees or above 8 degrees Celsius, and contact the pharmacy immediately.


Image Image Image Image